SI-BONE, Inc. (NASDAQ:SIBN) Director Sells $64,331.85 in Stock

SI-BONE, Inc. (NASDAQ:SIBN - Get Free Report) Director Jeffrey W. Dunn sold 3,377 shares of the business's stock in a transaction on Thursday, June 5th. The stock was sold at an average price of $19.05, for a total transaction of $64,331.85. Following the transaction, the director now directly owns 17,354 shares in the company, valued at approximately $330,593.70. The trade was a 16.29% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website.

SI-BONE Stock Down 0.2%

SIBN stock traded down $0.04 during mid-day trading on Monday, hitting $18.86. 293,360 shares of the company were exchanged, compared to its average volume of 383,088. The firm has a fifty day simple moving average of $16.10 and a 200 day simple moving average of $15.56. The company has a market capitalization of $803.72 million, a PE ratio of -20.50 and a beta of 0.94. SI-BONE, Inc. has a twelve month low of $11.70 and a twelve month high of $20.05. The company has a current ratio of 8.25, a quick ratio of 7.22 and a debt-to-equity ratio of 0.22.

SI-BONE (NASDAQ:SIBN - Get Free Report) last announced its quarterly earnings data on Monday, May 5th. The company reported ($0.15) earnings per share for the quarter, beating the consensus estimate of ($0.24) by $0.09. SI-BONE had a negative return on equity of 22.51% and a negative net margin of 23.82%. The firm had revenue of $47.29 million during the quarter, compared to analyst estimates of $45.13 million. On average, research analysts forecast that SI-BONE, Inc. will post -0.78 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of brokerages have commented on SIBN. Truist Financial boosted their price objective on shares of SI-BONE from $20.00 to $22.00 and gave the stock a "buy" rating in a report on Tuesday, May 6th. Needham & Company LLC reaffirmed a "buy" rating and set a $24.00 target price on shares of SI-BONE in a research report on Tuesday, May 6th. Finally, Cantor Fitzgerald reissued an "overweight" rating and issued a $25.00 price target on shares of SI-BONE in a report on Tuesday, May 6th.

Institutional Trading of SI-BONE

A number of institutional investors and hedge funds have recently made changes to their positions in SIBN. ANTIPODES PARTNERS Ltd bought a new position in SI-BONE during the 1st quarter worth $34,000. Virtus Fund Advisers LLC bought a new position in shares of SI-BONE during the fourth quarter worth about $40,000. Mainstream Capital Management LLC bought a new position in shares of SI-BONE during the fourth quarter worth about $53,000. GAMMA Investing LLC increased its holdings in shares of SI-BONE by 20,352.6% in the 1st quarter. GAMMA Investing LLC now owns 3,886 shares of the company's stock worth $55,000 after acquiring an additional 3,867 shares during the period. Finally, Virtus Advisers LLC bought a new stake in SI-BONE in the 1st quarter valued at about $58,000. 98.11% of the stock is currently owned by institutional investors and hedge funds.

About SI-BONE

SI-BONE, Inc, a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products.